Locoregional, as well as metastatic renal cell carcinoma, tends to relapse after nephrectomy or metastasectomy. Adjuvant therapy seems to be an effective strategy to reduce the risk of recurrence. All anti-VEGF tyrosine kinase inhibitors except sunitinib have failed to show any benefit in the adjuvant setting in patients with locally advanced disease and an intermediate-to-high chance of recurrence. On the other hand, immune checkpoint inhibitors, which are now used in the first-line in the metastatic setting, are being tested in the adjuvant setting. Pembrolizumab has shown benefit in the adjuvant setting in patients with a high risk of recurrence or with resected metastatic disease with no evidence of disease. Results for other checkpoint inhibitors are still awaited.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2022-0125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantitative assessment of the generalizability of a brain tumor Raman spectroscopy machine learning model to various tumor types including astrocytoma and oligodendroglioma.
J Biomed Opt
January 2025
McGill University, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada.
Significance: Maximal safe resection of brain tumors can be performed by neurosurgeons through the use of accurate and practical guidance tools that provide real-time information during surgery. Current established adjuvant intraoperative technologies include neuronavigation guidance, intraoperative imaging (MRI and ultrasound), and 5-ALA for fluorescence-guided surgery.
Aim: We have developed intraoperative Raman spectroscopy as a real-time decision support system for neurosurgical guidance in brain tumors.
Impact of hospital volume on survival in patients with locally advanced colon cancer - A Dutch population-based study.
Colorectal Dis
February 2025
Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.
Aim: Locally advanced colon cancer (LACC) often necessitates complex prognosis-determining treatment. This study investigated the impact of hospital volume on short- and long-term outcomes following surgery for LACC.
Method: Data involving all patients with LACC categorized as clinical T4 and/or N2, between 2015 and 2019 in the Netherlands, were extracted from the Netherlands Cancer Registry.
The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.
Cancers (Basel)
January 2025
Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
Cholangiocarcinoma (CCA) represents approximately 3% of all gastrointestinal cancers and is a highly heterogeneous and aggressive malignancy originating from the epithelial cells of the biliary tree. CCA is classified by anatomical location into intrahepatic (iCCA), extrahepatic (eCCA), gallbladder cancer (GBC), and ampullary cancers. Although considered a rare tumor, CCA incidence has risen globally, particularly due to the increased diagnosis of iCCA.
View Article and Find Full Text PDFFemale Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
Cancers (Basel)
January 2025
Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON M5G 1Z5, Canada.
The incidence of melanoma among young adults has risen, yet mortality has declined annually since the introduction of immune checkpoint inhibitors (ICI). The utilization of peri-operative ICI has significantly altered the treatment landscape in melanoma, with PD-1 inhibitors showing promising efficacy in improving relapse-free survival rates in high-risk stage II-III disease. With the increasing use of ICI, secondary concerns have emerged regarding the impact of cancer drugs on fertility and reproductive health among women of childbearing potential, especially in early-stage cancer settings.
View Article and Find Full Text PDF[Translated article] The relevance of therapeutic positioning in the post-approval evaluation of new drugs.
Farm Hosp
January 2025
Servicio de Farmacia, Hospital Universitario Puerto Real, Cádiz, Spain.
The objective of regulatory authorities is to ensure a favourable risk-benefit balance for medicines in their licenced indication, without seeking to establish their place in the therapeutic armamentarium beyond that. The licenced indication covers heterogeneous subpopulations and often does not sufficiently specify the characteristics of the patients who may benefit. The regulatory information does not always show the benefit over the standard treatment(s); moreover, it only reacts to the conditions specified in the developer's application, and lacks an assessment of the clinical relevance of the benefit and its uncertainties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!